Pharmacological Management of Obesity

Pharmacological Management of Obesity

Pharmacological Management of Obesity

On this page

Indications & Goals - Weighing the Options

  • Primary Goal: Achieve clinically significant weight loss (≥ 5-10% of initial body weight) to mitigate obesity-related health risks.
  • Indications (Indian/Asian Adults):
    • BMI ≥ 25 kg/m² (Obesity).
    • BMI ≥ 23 kg/m² (Overweight) with ≥ 1 significant comorbidity (e.g., T2DM, hypertension, dyslipidemia, OSA, CVD).
  • Pre-requisite: Pharmacotherapy is considered after failure of comprehensive lifestyle interventions (diet, physical activity, behavioral changes) for at least 3-6 months.
  • Key Considerations: Patient motivation, realistic goals, risk-benefit assessment for individual agents.

⭐ Pharmacotherapy for obesity is an adjunct to, not a substitute for, sustained lifestyle modifications.

Central Mechanisms - Brainy Weight Busters

Central agents modulate neurotransmitters or receptors in the hypothalamus (appetite regulation center) or reward pathways to reduce appetite or increase satiety.

AgentMOA HighlightsAvg. Wt. LossKey AEs/CIs (⚠️)
Phentermine/TopiramateNE release (↓appetite); GABA-R modulation (↑satiety)~9-11%Tachycardia, paresthesia. ⚠️ Glaucoma, hyperthyroidism, MAOI use. Teratogenic.
Naltrexone/Bupropionµ-opioid antagonist + DA/NE reuptake inhibitor (↓cravings, ↑POMC)~5-9%Nausea, headache. ⚠️ Seizures, uncontrolled HTN, opioid use. Black Box: Suicidality.
Liraglutide (Saxenda)GLP-1 RA (↑satiety, ↓gastric emptying) 📌 '-glutide'~5-8% (3mg)GI (nausea, vomiting), pancreatitis. ⚠️ Hx MTC/MEN2.
Semaglutide (Wegovy)GLP-1 RA (↑satiety, ↓gastric emptying) 📌 '-glutide'~15-17% (2.4mg)GI (nausea, vomiting), pancreatitis. ⚠️ Hx MTC/MEN2.

⭐ > Naltrexone/Bupropion synergistically targets both hypothalamic melanocortin pathways (reducing hunger) and mesolimbic reward pathways (reducing cravings).

Peripheral Mechanisms - Gut Feeling Fighters

  • Orlistat (Xenical, Alli)
    • MOA: Reversible inhibitor of pancreatic & gastric lipases.
      • Prevents hydrolysis of dietary triglycerides.
      • ↓ dietary fat absorption by ~30%.
    • Dose: 120 mg TID (with main meals containing fat).
    • Side Effects:
      • GI: Steatorrhea (oily spotting, flatus with discharge, fecal urgency). 📌 'Oily'stat.
      • ↓ absorption of fat-soluble vitamins (A, D, E, K) - supplement 2 hours apart.
    • Interactions: Warfarin (↑ INR via ↓ Vit K), Cyclosporine (↓ levels - administer 2-3 hours apart).

    ⭐ Orlistat is a peripherally acting lipase inhibitor; it does not affect appetite or satiety centers in the brain.

Drug Comparison & Safety - Safe Slimming Strategies

Drug Comparison: Key Features

DrugMOAEfficacy (Avg. WL)Key AEsKey CIs
OrlistatInhibits pancreatic/gastric lipase; ↓fat absorption~3-5%GI: Steatorrhea, fecal urgency, oily spottingChronic malabsorption, cholestasis
LiraglutideGLP-1 RA: ↑satiety, ↓appetite, delays gastric emptying~5-8%N/V/D, pancreatitis riskHx Medullary Thyroid Ca (MTC)/MEN2
SemaglutideGLP-1 RA: Potent; ↑satiety, ↓appetite, delays gastric emptying~10-15%N/V/D (often dose-dep.), pancreatitis riskHx MTC/MEN2
Naltrexone/BupropionNaltrexone (opioid antag) + Bupropion (NDRI): Modulates appetite~5%Nausea, headache, insomnia, ↑BP/HRSeizures, uncontrolled HTN, MAOI use, chronic opioid use
*   Goal: Clinically significant weight loss (≥**5%**).
*   Discontinue if <**5%** weight loss at **3 months** (12 weeks).
*   ⚠️ All generally contraindicated in pregnancy, breastfeeding.

⭐ GLP-1 RAs (Liraglutide, Semaglutide) offer cardiovascular benefits in T2DM patients, a crucial advantage beyond weight loss.

Simplified Drug Selection Flow

Loading diagram…

High‑Yield Points - ⚡ Biggest Takeaways

  • Orlistat: Lipase inhibitor; causes steatorrhea, fat-soluble vitamin deficiency. Monitor INR with warfarin.
  • GLP-1 agonists (Liraglutide, Semaglutide): Suppress appetite, delay gastric emptying; nausea common. Thyroid C-cell tumor risk.
  • Naltrexone/Bupropion: Opioid antagonist + DA/NE reuptake inhibitor. BBW: Suicidality.
  • Phentermine/Topiramate: Sympathomimetic + antiepileptic. Short-term use; CV risks, teratogenic.
  • Setmelanotide: MC4R agonist for rare genetic obesities (POMC, PCSK1, LEPR).
  • Crucial: Note contraindications (e.g., pregnancy, MAOIs) & key AEs for each drug class.

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Pharmacological Management of Obesity

  1. 1. Polyglandular syndrome (Schmidt syndrome) is associated with adrenocortical deficiency and which of the following conditions?

    • A. De Quervain thyroiditis
    • B. Hypoparathyroidism
    • C. Islet cell adenoma
    • D. Graves disease
    Show answer

    Answer: D. Graves disease

    Graves disease is an autoimmune thyroid disorder that can accompany primary adrenal insufficiency in Schmidt syndrome, or autoimmune polyglandular syndrome type 2. De Quervain thyroiditis is a painful subacute inflammatory thyroiditis rather than the autoimmune thyroid disease defining this association. Hypoparathyroidism is characteristic of autoimmune polyglandular syndrome type 1, not the usual Schmidt syndrome association. Islet cell adenoma is a pancreatic neuroendocrine tumour associated with MEN-1 rather than autoimmune polyglandular syndrome type 2.

  2. 2. A 25-year-old woman with an eating disorder has used laxatives for 9 months. Colonoscopy shows brown-black colonic pigmentation, and biopsy reveals pigment-laden macrophages in the lamina propria. Which laxative is most likely responsible?

    • A. Castor oil
    • B. Bisacodyl
    • C. Sennosides
    • D. Sorbitol
    Show answer

    Answer: C. Sennosides

    Sennosides - Chronic use of sennosides, anthraquinone laxatives, causes epithelial apoptosis and pigment accumulation, producing melanosis coli with dark brown to black colonic mucosa. - The biopsy finding of pigment-laden macrophages within the lamina propria confirms the characteristic histopathology associated with prolonged sennoside use. Bisacodyl - Bisacodyl is a stimulant laxative that acts locally in the colon to increase fluid and electrolyte secretion and stimulate peristalsis. - Although it promotes bowel movements, it does not typically cause melanosis coli with pigment-laden macrophages in the lamina propria. Sorbitol - Sorbitol is an osmotic laxative that draws water into the colon, softening stools and promoting bowel movements. - It does not produce the characteristic dark colonic mucosa or pigment-laden macrophages associated with melanosis coli. Castor oil - Castor oil is a stimulant laxative that acts primarily on the small intestine by increasing fluid secretion and intestinal motility. - It does not typically cause melanosis coli, the pigmentary change identified by dark mucosa and pigment-laden macrophages.

  3. 3. Which hormone does NOT primarily act through the cAMP second-messenger pathway?

    • A. Glucagon
    • B. Estrogen
    • C. Follitropin
    • D. Lutropin
    Show answer

    Answer: B. Estrogen

    Estrogen - Estrogen is a lipophilic steroid hormone that crosses the cell membrane and binds intracellular receptors. - The estrogen–receptor complex directly regulates gene transcription, so its primary mechanism does not depend on cAMP as a second messenger. Glucagon - Glucagon binds a Gs-coupled GPCR, activating adenylyl cyclase and increasing intracellular cAMP. - The resulting cAMP–protein kinase A pathway mediates glucagon’s effects, especially those regulating hepatic glucose metabolism. Lutropin - Lutropin binds a cell-surface Gs-coupled GPCR, which stimulates adenylyl cyclase and raises intracellular cAMP. - The cAMP pathway contributes to LH-mediated steroidogenesis and ovulation, so LH does not fit the exception. Follitropin - Follitropin binds a cell-surface Gs-coupled GPCR, activating adenylyl cyclase and increasing intracellular cAMP. - This cAMP signaling is important for FSH effects on gamete development, so FSH does not fit the exception.

  4. 4. A middle-aged male patient presents with protrusion of the chin, excessive sweating, impaired glucose tolerance, and enlargement of hands and feet. Which of the following is a growth hormone receptor antagonist used to treat this condition?

    • A. Pegvisomant
    • B. Lanreotide
    • C. Cabergoline
    • D. Octreotide
    Show answer

    Answer: A. Pegvisomant

    Pegvisomant - Pegvisomant binds growth hormone receptors, preventing growth hormone signaling and thereby reducing circulating IGF-1 levels. - The findings indicate acromegaly, for which pegvisomant is specifically used as a growth hormone receptor antagonist. Cabergoline - Cabergoline is a dopamine agonist that primarily suppresses prolactin secretion, rather than directly blocking growth hormone receptors. - Although it may have a limited role in acromegaly, particularly with prolactin co-secretion, it is not the requested growth hormone receptor antagonist. Lanreotide - Lanreotide is a somatostatin analogue used in acromegaly that suppresses growth hormone secretion rather than antagonizing growth hormone receptors. Octreotide - Octreotide is a somatostatin analogue that suppresses pituitary growth hormone secretion, rather than blocking growth hormone receptors. - It is useful in acromegaly, but its mechanism differs from the receptor antagonism specifically described in the question.

  5. 5. Which drug decreases the bone resorption in osteoporosis?

    • A. Cortisone
    • B. Teriparatide
    • C. Abaloparatide
    • D. Risedronate
    Show answer

    Answer: D. Risedronate

    Risedronate - Risedronate is a bisphosphonate that inhibits osteoclast activity, thereby decreasing bone resorption in patients with osteoporosis. - Reduced bone breakdown helps preserve bone mineral density, making risedronate the option that directly matches the question's mechanism. Cortisone - Cortisone is a glucocorticoid that, with long-term use, decreases bone formation and can increase bone resorption, worsening osteoporosis rather than treating it. - Although useful for inflammatory conditions, cortisone is not prescribed to reduce osteoclast-mediated bone loss; prolonged exposure instead increases osteoporosis risk. Teriparatide - Teriparatide is a parathyroid hormone analogue that primarily stimulates osteoblast activity, producing an anabolic effect and promoting new bone formation. - It treats osteoporosis through bone formation rather than primarily decreasing bone resorption, so it does not best match the mechanism asked here. Abaloparatide - Abaloparatide is a PTH1-receptor agonist used in osteoporosis primarily to stimulate bone formation rather than inhibit osteoclast-mediated bone resorption.

  6. 6. At which positions does pancreatic lipase hydrolyze the ester linkages of triacylglycerides?

    • A. 3
    • B. 1 and 2
    • C. 2 and 3
    • D. 1 and 3
    Show answer

    Answer: D. 1 and 3

    1 and 3 - Pancreatic lipase specifically hydrolyzes the sn-1 and sn-3 ester bonds of triacylglycerol, the two primary alcohol positions on glycerol. - This regiospecific action forms 2-monoacylglycerol and two free fatty acids while sparing the sn-2 ester bond. 1 and 2 - Pancreatic lipase hydrolyzes the sn-1 and sn-3 ester bonds, not both the outer sn-1 and middle sn-2 positions. - Hydrolysis at positions 1 and 2 would produce a 3-monoacylglycerol, unlike the characteristic 2-monoacylglycerol formed during pancreatic fat digestion. 3 - Pancreatic lipase acts at both outer glycerol positions, so hydrolysis is not limited to position 3. - Hydrolysis only at position 3 would yield a diacylglycerol intermediate and one free fatty acid, rather than the usual two free fatty acids and 2-monoacylglycerol. 2 and 3 - Hydrolysis at positions 2 and 3 would leave a 1-monoacylglycerol, which is not the characteristic product of pancreatic lipase. - The enzyme generally spares the sn-2 position and preferentially cleaves the two outer sn-1 and sn-3 positions.

  7. 7. What is the most common gastrointestinal side effect of oral contraceptives?

    • A. Appetite loss
    • B. Weight loss
    • C. Nauseousness
    • D. Constipation
    Show answer

    Answer: C. Nauseousness

    Nauseousness - Nauseousness is the most common gastrointestinal side effect of oral contraceptives, particularly during the initial weeks, largely due to the estrogen component. - This symptom often improves with continued use as the body adjusts and may be reduced by taking the pill with food or at bedtime. Appetite loss - Appetite loss is not a common gastrointestinal effect of oral contraceptives; hormonal fluctuations may instead increase appetite in some individuals. - Effects on appetite and metabolism vary between users, but a consistent association with decreased appetite has not been demonstrated. Weight loss - Weight loss is not typically associated with oral contraceptive use; some users may report slight weight gain instead. - Reported weight changes are more often related to fluid retention than true loss of body fat, making this an unsuitable answer. Constipation - Constipation is not a frequent gastrointestinal adverse effect of oral contraceptives, although some users may notice nonspecific bowel-habit changes. - When gastrointestinal symptoms occur, diarrhea is reported more commonly than constipation, so this option does not best fit the question.

  8. 8. Which direct electrophysiological effect best explains the characteristic ventricular arrhythmias of bupivacaine cardiotoxicity?

    • A. Depressed myocardial conduction
    • B. Depressed sinoatrial automaticity
    • C. Slowed atrioventricular nodal conduction
    • D. Prolonged ventricular repolarization
    Show answer

    Answer: A. Depressed myocardial conduction

    Depressed myocardial conduction is the best answer. Cardiac fast sodium-channel blockade is the principal mechanism of bupivacaine cardiotoxicity. Slow dissociation from these channels depresses myocardial conduction and promotes ventricular arrhythmias; myocardial contractile depression also contributes. Depressed sinoatrial automaticity primarily slows the heart rate rather than explaining the characteristic ventricular arrhythmias. Slowed atrioventricular nodal conduction impairs atrioventricular transmission rather than explaining the characteristic ventricular arrhythmias. Prolonged ventricular repolarization is not the principal arrhythmogenic effect here; bupivacaine primarily slows fast sodium-channel-dependent myocardial conduction.

  9. 9. In a healthy person, a rise in blood glucose directly stimulates secretion of which hormone?

    • A. Pituitary somatotropin
    • B. Pancreatic glucagon
    • C. Adrenal cortisol
    • D. Pancreatic insulin
    Show answer

    Answer: D. Pancreatic insulin

    Pancreatic insulin - Insulin is secreted by pancreatic β-cells in response to hyperglycemia; glucose metabolism raises ATP, closes K⁺ channels, and triggers insulin release. - As glucose rises within the physiological range, insulin secretion increases to promote glucose uptake and storage, making insulin the appropriate hormone. Pituitary somatotropin - Growth hormone secretion is generally suppressed by hyperglycemia rather than increasing linearly with rising blood glucose concentrations. - GH is a diabetogenic hormone that antagonizes insulin action and is more typically stimulated by hypoglycemia or other physiological stresses. Pancreatic glucagon - Glucagon secretion from pancreatic α-cells is inhibited when blood glucose rises, because counter-regulation is unnecessary during hyperglycemia. - Glucagon normally increases during hypoglycemia, promoting hepatic glycogenolysis and gluconeogenesis rather than responding positively to elevated glucose. Adrenal cortisol - Cortisol secretion is regulated primarily through the hypothalamic–pituitary–adrenal axis, not by a direct linear response to increasing blood glucose. - Cortisol promotes gluconeogenesis and contributes to hyperglycemia during stress, but elevated glucose does not directly stimulate its secretion in this manner.

  10. 10. A patient with pulmonary fibrosis comes to the emergency with arrhythmia. Which anti-arrhythmic drug should be avoided?

    • A. Lignocaine
    • B. Procainamide
    • C. Verapamil
    • D. Amiodarone
    Show answer

    Answer: D. Amiodarone

    Amiodarone - Amiodarone can cause significant pulmonary toxicity, including worsening of pre-existing pulmonary fibrosis, so it should be avoided in this patient. - Its long half-life and iodine content contribute to delayed, potentially severe pulmonary adverse effects, making it unsuitable when underlying lung disease is present. Procainamide - Procainamide, a Class IA anti-arrhythmic, can treat atrial and ventricular arrhythmias without the characteristic pulmonary toxicity associated with amiodarone. - Its important adverse effects include lupus-like syndrome, agranulocytosis, and cardiotoxicity, which are not specifically worsened by pulmonary fibrosis. Lignocaine - Lignocaine, a Class IB anti-arrhythmic, is mainly used for ventricular arrhythmias and does not cause significant pulmonary toxicity, so pulmonary fibrosis is not a reason to avoid it. - Its principal toxicities involve the central nervous system and cardiovascular system, particularly with excessive dosing, rather than direct lung injury. Verapamil - Verapamil is a non-dihydropyridine calcium channel blocker used for supraventricular tachycardias and rate control in atrial fibrillation, without significant pulmonary toxicity. - Its major concerns are cardiac depression and hypotension, not worsening pulmonary fibrosis; therefore, it is not the best answer to this question.

Flashcards: Pharmacological Management of Obesity

  1. 1. The _____ pharmacological action of metformin is to _____

    Show answer

    central · reduce hepatic gluconeogenesis.

  2. 2. is a dual SGLT-1/2 inhibitor

    Show answer

    Sotagliflozin

  3. 3. Thiazolidinediones (glitazones) can cause weight _____ and increased _____ Function Tests

    Show answer

    gain · Liver

  4. 4. Monotherapy of _____ and _____ have a weight-_____ effect.

    Show answer

    sulfonylureas · insulin · gain

  5. 5. Alpha-glucosidase inhibitors (e.g. acarbose, miglitol) are infrequently prescribed due to their ability to cause _____, _____, and abdominal pain as side effects

    Show answer

    diarrhea · flatulence

  6. 6. Drug of choice as antidiabetic in obese patient:

    Show answer

    Metformin

  7. 7. What type(s) of diabetes may be treated with GLP-1 agonists and DPP-4 inhibitors? _____

    Show answer

    T2DM only

  8. 8. gossypol is _____

    Show answer

    a male contraceptive

  9. 9. EZY pill contains _____

    Show answer

    LNG 1.5 mg — LNG is progesterone

  10. 10. Uses of the SERM Centchroman (Ormeloxifene) include _____ and _____

    Show answer

    contraception · dysfunctional uterine bleeding (DUB) — Centchroman (brand names: Chhaya, Saheli) is a non-steroidal, non-hormonal once-a-week pill.

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF